We have recently described a novel modular targeting platform for T cell recruitment that not only efficiently replaces but also is superior to conventional T cell-engaging bispecific antibodies as it allows for the flexible targeting of several antigens and the delivery of co-stimulatory ligands to malignant lesions, thereby enhancing the antitumor potential of redirected T cells.
Keywords: CD137; CD33; T-cell retargeting; acute myeloid leukemia; co-stimulatory ligands; immunotherapy; modular targeting system; single-chain bispecific antibodies.